---
title: Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia
date: '2024-01-19'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38241630/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240120170611&v=2.18.0
source: Blood
description: For patients with high-risk or relapsed/refractory acute myeloid leukemia
  (AML), allogeneic stem cell transplantation (alloHSCT) and the graft-versus-leukemia
  effect mediated by donor T cells, offer the best chance of long-term remission.
  However, the concurrent transfer of alloreactive T cells can lead to graft-versus-host
  disease that is associated with transplant-related morbidity and mortality. Furthermore,
  ~60% of patients will ultimately relapse post-alloHSCT, thus underscoring the ...
disable_comments: true
---
For patients with high-risk or relapsed/refractory acute myeloid leukemia (AML), allogeneic stem cell transplantation (alloHSCT) and the graft-versus-leukemia effect mediated by donor T cells, offer the best chance of long-term remission. However, the concurrent transfer of alloreactive T cells can lead to graft-versus-host disease that is associated with transplant-related morbidity and mortality. Furthermore, ~60% of patients will ultimately relapse post-alloHSCT, thus underscoring the ...